TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
about
Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells.Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivoPDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signalsDiscovery and clinical introduction of first-in-class imipridone ONC201.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.Geraniin suppresses tumor cell growth and triggers apoptosis in human glioma via inhibition of STAT3 signaling.A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.The inhibiting effect of neural stem cells on proliferation and invasion of glioma cells.Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death.Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
P2860
Q37022290-33EDC7A5-ACA7-473B-8DA3-98DD2362504CQ37109638-C5DD375B-D512-49A6-BBF2-CA0C3B21B156Q37376084-F9242EE9-CB96-4893-AE23-A2B660EEAD21Q37619702-16D744D2-459D-4445-86B2-933EFB57A8E3Q37687570-D6334076-2612-408D-831E-9CB123C34813Q38677019-AD57D9D6-B7C5-4CC1-B499-682066769E32Q38829723-1920D77A-5B1E-48EC-81F6-2A13AD5CB70FQ38857150-2DF80D27-ABF1-4165-B4E2-A1F626E211A8Q39811568-7CE42D5F-CADC-4B0D-8EE1-9784A3240960Q41043950-32C074B7-B09A-4139-8D4F-14ABA82185A7Q41566564-90B55126-7EC3-4A23-A70E-BA1CDDC4C70FQ41879630-31E07DB3-47B7-418F-904B-C54BD9A722B7Q42365296-36883E93-67AF-41D2-8DBC-EEDE98E8C259Q42652909-39EE581E-E853-4D6A-AD11-CCD034C3FBAEQ45559181-A4596945-B4FF-4166-B11E-DE7147665FF0Q47103469-9BF9D3FC-1C49-4B91-9BC9-48A1120BAAD0Q47115416-A70FA756-25C6-46F0-A2D2-227C409F7FB8Q48158175-11C31993-F0EB-494D-B85A-DF5762689FF7Q49207979-6E04738D-4BE1-4A3A-9DC3-4CBA91B5779FQ50204389-48FA9D9B-A01D-488E-9775-F6C74BBF52D7Q55263786-D92D948C-35A6-4FDE-AFD4-8561FF1F8AB7Q58603251-0B5DC123-D4B3-4054-BFF2-5CCD483707F7
P2860
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@ast
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@en
type
label
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@ast
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@en
prefLabel
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@ast
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@en
P2093
P2860
P50
P356
P1433
P1476
TIC10/ONC201 synergizes with B ...... partners in vitro and in vivo.
@en
P2093
Jeffrey N Bruce
Markus D Siegelin
Maïmouna Bâ
Peter Canoll
P2860
P304
36456-36471
P356
10.18632/ONCOTARGET.5505
P407
P577
2015-10-12T00:00:00Z